Clozapine in treatment-resistant schizophrenia: Followed-up study for three years;Tedaviye dirençli şizofrenide klozapin: Üç yillik i̇zlem

Klinik Psikofarmakoloji Bulteni

Volumn 10, Issue 2, 2000, Pages 74-80

  Uzun, Özcan ^a   Özşahin, Aytekin ^a   Özmenler, K Nahit ^a   Doruk, Ali ^b   Battal, Salih ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KIBRIS ^*  (Turkey)

Author keywords

Clozapine; Three years follow up; Treatment resistant schizophrenia

Indexed keywords

EID: 4244198747     PISSN: 10177833     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Meltzer HY: Clozapine, pattern of efficacy in treatment - resistant schizophrenia: Novel Antipsychotic Drugs. Raven Press Ltd, New York, 1992:33-46.
2. Lindström LH: The effect of long - term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psych Scand, 1988;77:524-529.
3. Meltzer HY: Clozapine and other atypical neuroleptics: efficacy, side effects, optimal utilization. J Clin Psychiatry, Monograph Series, 1994;12:38-42.
4. Meltzer HY: Multiple - outcome criteria in schizophrenia: an overview of outcome with clozapine. Eu Psychiatry, 1995;10(Suppl 1)19-25.
5. Coşar B, Taner E, Ankan Z, Işik E: Kronik şizofrenide klozapin etkinliǧi: 111 hasta üzerinde 2 yillik izlem çalişmasi. 34. Ulusal Psikiyatri Kongresi Özet Kitabi, Izmir 1998:239.
6. Soylu C, Bilici M, Bekaroglu M, Yildinm F: Tedaviye dirençli bir grup şizofrenili hastada klozapinin etkinliǧi. Klinik Psikofarmarmakoloji Bülteni, 1999;9:34-38.
7. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT: Effect of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry, 1994;151:20-26.
8. Carpenter WT, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry, 1995;152:827-832.
9. Taner E, Coşar B, Ankan Z, Işik E: İki yillik klozapin tedavisinin kronik şizofrenide pozitif ve negatif belirtiler üzerine etkisi. 34. LJlusal Psikiyatri Kongresi Özet Kitabi, İzmir 1998:238.
10. Meltzer HY: Clozapine: clinical advantages and biologic mechanisms. In: 'Schizophrenia, Scientific Progress' Inter-national Congress on Schizophrenia, Bethesda, 1987;s.302-309.
11. Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin, 1991;17:263-287.
12. Meltzer HY, Bastani B, Kwon KY, ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients, 1. Preliminary report. Psychopharmacol, 1989;99 (Suppl 1)68-72.
13. Tol H: Symposium. Molecular biology of the dopamine system: Heterogeneity of the dopamine receptors. Abstract from 21st. Annual Meeting of Society for Neuroscience, New Orleans, 1991.
14. Grace J, Bellus SB, Raulin ML,Herz Ml, Priest BL, Brenner V, Donnelly K, Smith P, Gunn S: Long-term impact of clozapine and psychospcial treatment on psychiatric symptoms and cognitive functioning. Psychiaric Services, 1996;47:41-45.
15. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S: Clozapine: plasma levels and prolactin response. Psychopharmacol, 1981;73:184-187.
16. Grohmann M.R, Ruther E, Sassim N, Schmidt LG: Adverse effects of clozapine. Psychopharmacol, 1989;99:101-104.
17. Povlsen UJ, Noring U, Fog R, Gerlach J: Tolerability and therapeutic effect of clozapine for up to 12 years. Acta Psychiatr Scand, 1985;71:176-185.
18. Pickar D: Clozapine and other atypical neuroleptics: efficacy, side effects, optimal utilization (Discussion). J Clin Psychiatry, Monograph Series, 1994;12:43-45.
19. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR: The side-effects of clozapine, a four year follow-up study. Prog Neuro-psycopharmcol Bio Psychiatry, 1994; 18:537-544.
20. Schmauss M, Wolff R, Erfurth A, Rüther E:Tolerability of long term clozapine treatment. Psychopharmacol, 1989; 99:105-108.
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised, American Psychiatric Press, Washington DC, 1987.
22. UK Clozapine Study Group: The safety and efficacy of clozapine in severe treatment - resistant schizophrenic patients in the UK. Br J Psychiatry, 1993;163:150-154.
23. Overall JE, Gorham DR: Brief Psychiatric Rating Scale. Psychol Rep, 1962;10:799-812.
24. Andreasen NC: The Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City, 1984.
25. Andreasen NC: The Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa City, 1984.
26. Soykan C: Institutional differences and case typicality as related to diagnosis system severity, prognosis and treatment. Master Tezi, Ortadoǧu Teknik Üniversitesi, Ankara 1989.
27. Erkoç Ş, Arkonaç O, Atakli C, ve ark: Negatif semptomlan deģerlendirme ölçeǧinin güvenirlirliǧi ve geçerliliǧi. Düşü nen Adam, 1991;4:16-19.
28. Erkoç Ş, Arkonaç O, Atakli C, ve ark: Pozitif semptomlan deǧerlendirme ölçeǧinin güvenirlirliǧi ve geçerliliǧi. Düşü nen Adam, 1991;4:20-24.
29. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU) The UKU Side Effect Rating Scale, English Version, Hillerod, 1986.
30. Lindenmayer JP, Grochowski S, Mabugat L: Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol, 1994;14:201-204.
31. Kane JM: The efficacy of clozapine in the treatment of schizophrenia: A long-term perspective. J Clin Psychiatry Monograph, 1990;8:9-14.
32. Naber D, Leppig M, Grohmann R, Hippius H: Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia. Psychopharmacol, 1989;99 (Suppl):73-76.
33. Keks NA, Copolov LD, Johnson G: Initial Australian experience with the atypical antipsychotic clozapine. Med J Aust, 1993;159:638-639.
34. Anhan G, Dilbaz N, Tan D: Tedaviye dirençli şizofrenik hastalarda klozapinin etkinliǧi. Düşünen Adam, 1996; 9:34-39.
35. Tühonen J, Nousiainen LJ, Hakola P, Leinonen E, Tuunainen A, Mervaala E, Paanila J: EEG abnormalities associated with clozapine treatment. Am J Psychiatry, 1991 ;148:1406.
36. Honigfeld G, Patin J: A two-year clinical and economic follow-up of patients on clozapine. Hosp Com Psychiatry, 1990;41:882-885.
37. Alvir JM, Lieberman JA, Safferman AZ, schwimmer JL, Schaaf JA: Clozapine- induced agranulocytosis. N Engl J Med, 1993;329:162-167.
38. Gaulin BD, Markowitz JS, Caley C, Nesbitt LA, Dufresne RL:Clozapine-associated elevation in serum triglycerides. Am J Psychiatry, 1999;156:1270-1272.
39. Meltzer HY: The neuroendocrine profile of clozapine, an atypical antipsychotics agent. J Clin Psychiatry Monograph, 1990;8:15-21.
40. Isermann H, Haupt R: Auffallige EEG-veranderungen under clozapin-behandlung bei paranoid halluzinatorichen psychosen. Nervenarzt, 1976;47:268.